Entera Bio (ENTX) Q2 2026 earnings summary

Executive summary

• Focused on developing first-in-class oral peptides for chronic conditions, with lead candidates EB613 (osteoporosis), EB612 (hypoparathyroidism), and EB618 (obesity/metabolic disorders).

• Achieved FDA alignment for a 12-month Phase 3 study of EB613, with initiation planned for late 2026 and topline data expected in the second half of 2028.

• Raised $275 million in an oversubscribed private placement in July 2026 to fund EB613 through anticipated NDA submission and extend cash runway into 2030.

• Expanded collaboration with OPKO for EB612 and EB618, sharing development costs and economics.

• Presented positive Phase 1/2 data for EB613 and robust preclinical data for EB612 and EB618 at major scientific meetings.

Financial highlights

• Operating loss for Q2 2026 was $4.6M, up 71% year-over-year; net loss for Q2 2026 was $7.3M, up 175% year-over-year, driven by a $2.7M non-cash fair value remeasurement of pre-funded warrants.

• Cash, cash equivalents, and restricted cash totaled $18.4M as of June 30, 2026, prior to the July financing; pro forma cash post-placement expected to fund operations into 2030.

• R&D expenses for Q2 2026 were $3.2M (up 111% YoY); G&A expenses were $1.4M (up 19% YoY).

• No product revenue recognized in 2026; prior year revenue was $42K from research services.

Outlook and guidance

• EB613 Phase 3 trial to begin late 2026, with topline results anticipated in the second half of 2028 and NDA submission planned thereafter.

• IND-enabling studies for EB612 ongoing, with IND filing targeted for the first half of 2027.

• Cash runway extended into 2030 following July 2026 private placement, expected to fully fund EB613 Phase 3 and support operations.

• Expectation of increased operating expenses as clinical programs advance.